DOAC Management for Dental Procedures
For most dental procedures, hold the DOAC for 1 day (skip the dose the day before the procedure) if the patient has normal renal function (CrCl >50 mL/min), and resume 24 hours after the procedure once hemostasis is achieved. 1
Pre-Procedure Management
Standard Dental Procedures (Low-to-Moderate Bleeding Risk)
Most dental work—including simple extractions, fillings, and routine periodontal procedures—falls into the low-to-moderate bleeding risk category. The 2022 American College of Chest Physicians guideline provides clear direction here 1:
- Hold for 1 calendar day before the procedure (not 24 hours, but skip the dose the day before)
- This applies when creatinine clearance is >30 mL/min
- No bridging with heparin is needed 1, 2
Dosing schedule specifics:
- If taking DOAC twice daily: Last dose should be the morning of the day before the procedure
- If taking DOAC once daily in the morning: Last dose should be the morning of the day before the procedure
- If taking DOAC once daily in the evening: Last dose should be two evenings before the procedure 2
Adjustments Based on Renal Function
The French GIHP guidelines emphasize that dabigatran requires longer interruption times due to renal elimination 2:
- CrCl >50 mL/min: Hold for 2 days (standard 1-day hold may be insufficient for dabigatran)
- CrCl 30-50 mL/min: Hold dabigatran for 4 days; hold rivaroxaban/apixaban/edoxaban for 2-3 days
- CrCl <30 mL/min: Requires individualized assessment with possible drug level monitoring 2
For the xabans (rivaroxaban, apixaban, edoxaban), the standard 1-day hold applies across most renal function levels when CrCl >30 mL/min 2.
Post-Procedure Resumption
Resume the DOAC 24 hours after the procedure once adequate hemostasis is confirmed 1. The evidence strongly supports this timeline:
- For low-to-moderate bleeding risk procedures: 24 hours post-procedure
- Ensure no active bleeding before restarting
- No need for prophylactic-dose heparin bridging in the interim 1, 2
Recent observational data from 523 patients undergoing oral surgery showed that continuing DOACs without interruption significantly increased bleeding risk (15.9 events per 100 person-months vs 5.9 for those who held the medication), with 90% of bleeding events occurring within 7 days post-procedure 3. This reinforces the importance of the brief interruption strategy.
Special Considerations
High-Risk Procedures
If the dental procedure involves extensive tissue manipulation, multiple extractions, or alveolar surgery, consider this high bleeding risk:
- Hold DOACs for 2-3 days pre-procedure 1
- For dabigatran with CrCl 30-50 mL/min: Hold for 4-5 days 2
- Resume 48-72 hours post-procedure 1
Early Phase VTE
Critical caveat: If this patient is in the early phase of acute DVT/PE treatment (first 3 weeks for rivaroxaban, first 7 days for apixaban when using higher loading doses), the standard protocol does not apply 2. This requires multidisciplinary discussion as the thrombotic risk is substantially elevated. Consider:
- Delaying elective procedures if possible
- Heparin bridging if procedure cannot be delayed
- Consultation with the prescribing physician
No Bridging Required
A key point of consensus across all guidelines: Do not bridge with LMWH or UFH for routine dental procedures in VTE patients 1, 2. The thrombotic risk during a 1-2 day interruption is minimal, and bridging increases bleeding risk without benefit.
Common Pitfalls to Avoid
Don't count "24 hours"—count calendar days: The 1-day hold means skipping the dose the day before, not calculating exact hours 1
Don't forget to check renal function: Especially for dabigatran, where CrCl <50 mL/min requires extended interruption 2
Don't use the same timing for all DOACs: Dabigatran needs longer interruption than the xabans due to renal clearance 2
Don't restart too early: Wait for confirmed hemostasis, typically 24 hours minimum 1
Don't bridge routinely: This patient's VTE history alone does not justify heparin bridging for dental work 1, 2